The perioperative enfortumab vedotin plus pembrolizumab (EV-P) substantially increased the frequency of adverse events (AEs), ...

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...

Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with ...

Immunocompromised patients with bladder cancer who undergo TURBT followed by BCG immunotherapy have worse survival outcomes compared to non-immunocompromised patients, a study suggests.

The Phase III study was held in Chinese locations and the HER2-targeting ADC Aidixi is unlikely to launch in markets outside ...

From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ...

Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of ...

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the ...

In patients with early-stage HER2-positive breast cancer in the DESTINY-Breast 05 and the DESTINY-Breast 11 trials, ...